1-3 of 3
Karin Jordan, MD
Close
Sort by
Journal Articles

Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma

Lukas John, Kaya Miah, Axel Benner, Elias K Mai, MD, Katharina Kriegsmann, MD, Michael Hundemer, MD, Carsten Mueller-Tidow, MD, Karin Jordan, MD, Hartmut Goldschmidt, MD, Marc S. Raab, MD, Nicola Giesen, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14.
https://doi.org/10.1182/blood-2020-136686
Published: 2020
Journal Articles

Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study

Simone Baldini, MD, Cristina Rossi, PhD, Michele Spina, MD, Massimo Federico, MD, Zsolt Nagy, MD, Karin Jordan, MD PhD, Igor Aurer, MD PhD, Josep-Maria Ribera, MD PhD, Gabriela Borsaru, MD, Nataliia Glushko, MD, Sebastian Grosicki, MD, Alexander Pristupa, MD, Alberto Bosi, MD, Eduardo M. Rego, MD PhD, Andrea Nizzardo, PhD, Simona Scartoni, PhD, Alessandra Scordari, PhD, Mariagiuseppa Matera, PhD, Carlo Alberto Maggi, MD PhD, Angela Capriati, MD PhD, Cecilia Simonelli, MD
Journal: Blood
Blood (2014) 124 (21): 5979.
https://doi.org/10.1182/blood.V124.21.5979.5979
Published: 2014
Journal Articles

Lenograstim Treatment Following Cytotoxic Therapy in Tumor Patients.

Hans-Heinrich Wolf, MD, Ilka Krohn, MD, Christoph Sippel, MD, Karin Jordan, MD, Wieland Voigt, MD, William Krueger, MD
Journal: Blood
Blood (2007) 110 (11): 4076.
https://doi.org/10.1182/blood.V110.11.4076.4076
Published: 2007